RecruitingPhase 1NCT06979674

Study of ESG406 in Adults With Solid Tumors

An Open-Label, Multiple Dose, Dose Escalation and Cohort Expansion Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of ESG406 in Subjects With Locally Advanced/Metastatic Solid Tumors

Sponsor

Shanghai Escugen Biotechnology Co., Ltd

Enrollment

556 participants

Start Date

Jun 4, 2025

Study Type

INTERVENTIONAL

Conditions

Locally Advanced/Metastatic Solid Tumors

Summary

This study is an open-label, dose-escalation and cohort expansion Phase I study, aiming to evaluate the safety, tolerability, PK characteristics and preliminary efficacy of ESG406, and determine the MTD, RP2D and administration regimens of ESG406. The study includes the dose escalation study in Phase Ia and the cohort expansion study in Phase Ib.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ESG406 for people with locally advanced/metastatic solid tumors. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGESG406

Administered via intravenous (IV) infusion.

Locations(3)

Chongqing University Cancer Hospital

Chongqing, Chongqing Municipality, China

The First Affiliated Hospital of Xi 'An Jiaotong University

Xi’an, Shanxi, China

The Second Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06979674

Related Trials